{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T01:21:12Z","timestamp":1788225672829,"version":"build-2803163510"},"reference-count":16,"publisher":"ALUNA","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Wiad Lek"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:p>The aim: Study of the clinical and hemodynamic effects of S-amlodipine in patients with arterial hypertension associated with coronary artery disease, in individuals with preserved LV systolic function. \nMaterials and methods: The study includes 51 patients with arterial hypertension associated with coronary artery disease, who were treated with S-amlodipine. \nResults: This study shows the high clinical effectiveness of the use of S-amlodipine in patients with arterial hypertension associated with coronary artery disease. We reveal that treatment of hypertensive patients with coronary artery disease with S-amlodipine leads to improvement of LV diastolic dysfunction, bringing it closer to normal values. \nConclusions: Clinical effectiveness was associated with positive changes in hemodynamics, and was expressed in the normalization of the left ventricle diastolic function parameters, about which indirectly indicates decreasing of end-diastolic pressure.<\/jats:p>","DOI":"10.36740\/wlek202311114","type":"journal-article","created":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T13:31:04Z","timestamp":1703165464000},"page":"2429-2434","source":"Crossref","is-referenced-by-count":3,"title":["S-AMLODIPINE AS A MODERN EFFECTIVE ANTIHYPERTENSIVE AND AN ANTIANGINAL AGENT"],"prefix":"10.36740","volume":"76","author":[{"given":"Ivan V.","family":"Chopei","sequence":"first","affiliation":[{"name":"UZHHOROD NATIONAL UNIVERSITY, UZHHOROD, UKRAINE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ksenia I.","family":"Chubirko","sequence":"additional","affiliation":[{"name":"UZHHOROD NATIONAL UNIVERSITY, UZHHOROD, UKRAINE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mykhailo V.","family":"Bychko","sequence":"additional","affiliation":[{"name":"UZHHOROD NATIONAL UNIVERSITY, UZHHOROD, UKRAINE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mykhaylo M.","family":"Hechko","sequence":"additional","affiliation":[{"name":"UZHHOROD NATIONAL UNIVERSITY, UZHHOROD, UKRAINE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonina V.","family":"Kedyk","sequence":"additional","affiliation":[{"name":"UZHHOROD NATIONAL UNIVERSITY, UZHHOROD, UKRAINE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan I.","family":"Kogutych","sequence":"additional","affiliation":[{"name":"UZHHOROD NATIONAL UNIVERSITY, UZHHOROD, UKRAINE"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22436","published-online":{"date-parts":[[2023]]},"reference":[{"key":"ref0","unstructured":"1. Amosova KM. Porivnialna otsinka antyanhinalnoi efektyvnosti ta perenosymosti livoobertaiuchoho izomeru amlodypinu i oryhinalnoho amlodypinu u khvorykh na esentsialnu arterialnu hipertenziiu. [Comparative assessment of the antianginal efficacy and tolerability of the levorotatory isomer of amlodipine and the original amlodipine in patients with essential arterial hypertension]. Spetsializovanyy medychnyy portal. 2015. https:\/\/health-ua.com\/article\/15521-porvnyalna-otcnka-antigpertenzivno-efektivnost-ta-perenosimost-lvoobertayuc [date access 20.05.2023] (In Ukrainian)."},{"key":"ref1","unstructured":"2. Bychko MV. Antahonisty kaltsiiu v likuvanni khvorykh na arterialnu hipertenziiu asotsiiovanu iz ishemichnoiu khvoroboiu sertsia [Calcium antagonists in the treatment of patients with arterial hypertension associated with coronary heart disease]. Uzhhorod: Lira. 2019, p. 248. https:\/\/dspace.uzhnu.edu.ua\/jspui\/handle\/lib\/47306 [date access 20.05.2023] (In Ukrainian)."},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Sen S, Demir M, Yigit Z, \u00dcresin AY. Efficacy and safety of S-amlodipine 2.5 and 5 mg\/d in hypertensive patients who were treatment-naive or previously received antihypertensive monotherapy. J Cardiovasc Pharmacol Ther. 2018;23(4):318-328. doi: 10.1177\/1074248418769054.","DOI":"10.1177\/1074248418769054"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Dalal J, Mohan JC, Iyengar SS et al. S-Amlodipine: an isomer with difference-time to shift from racemic amlodipine. Int J Hypertens. 2018; 2918:8681792. doi: 10.1155\/2018\/8681792.","DOI":"10.1155\/2018\/8681792"},{"key":"ref4","unstructured":"5. Lutai MI, Lysenko HF. Efektyvnist preparatu amlodypinu (stamlo) u patsiientiv z ishemichnoiu khvoroboiu sertsia v poiednanni z arterialnoiu hipertenziieiu [The effectiveness of the drug amlodipine (stamlo) in patients with coronary heart disease in combination with arterial hypertension]. Ukr. kardiol. zhurn. 2001; 2: 87-99. (In Ukrainian)."},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. Chen Q, Huang Q, Kang Y et al. Efficacy and tolerability of initial high vs low doses of S-(-)-amlodipine in hypertension. The Journal of Clinical Hypertension. 2017; 19(10): 973\u2013982. doi: 10.1111\/jch.13022.","DOI":"10.1111\/jch.13022"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. Sica DA. Pharmacotherapy review: calcium channel blockers. J Clin Hypertens. 2006; 8(1):53-56. doi: 10.1111\/j.1524-6175.2005.04140.x.","DOI":"10.1111\/j.1524-6175.2005.04140.x"},{"key":"ref7","unstructured":"8. Netiazhenko VZ., Bychko MV. Klinichna efektyvnist amlodypina u khvorykh arterialnoiu hipertenziieiu v poiednanni z ishemichnoiu khvoroboiu sertsia [Clinical effectiveness of amlodipine in patients with arterial hypertension in combination with coronary heart disease]. Naukovyi visnyk UzhNU. Seriia \u201eMedytsyna\u201d. 2003; 21: 126\u2013130. (In Ukrainian)."},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. Maksimova MA, Lukina YV, and Martsevich SY. The role of S-amlodipine in arterial hypertension therapy with combination of calcium channel blockers and beta-blockers. Ration Pharmacother Cardiol. 2013; 9: 236\u2013240. doi:10.20996\/1819-6446-2013-9-3-236-240.","DOI":"10.20996\/1819-6446-2013-9-3-236-240"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10. Canau A, Devereux RB, Roman MJ. Patterns of left ventricular hypertrophy in essential hypertension. J. Amer. Coll. Cardiology. 1992; 12:1550-1558. doi:10.1016\/0735-1097(92)90617-v.","DOI":"10.1016\/0735-1097(92)90617-v"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Mohan JC, Iyengar SS, Hiremath J et al. \u201cS-Amlodipine: An Isomer with Difference \u2013 Time to Shift from Racemic Amlodipine\u201d. International Journal of Hypertension. 2018. doi: 10.1155\/2018\/8681792.","DOI":"10.1155\/2018\/8681792"},{"key":"ref11","unstructured":"12. Netiazhenko VZ, Bychko MV. Sposib otsinky efektyvnosti likuvannia khvorykh na ishemichnu khvorobu sertsia z stenokardiieiu napruzhennia ta arterialnoiu hipertenziieiu amlodypinom [The method of evaluating the effectiveness of treatment of patients with coronary heart disease with angina pectoris and arterial hypertension with amlodipine] Patent na korysnu model \u2116 30491 vid 25.02.2008\u0440, vlasnyk patentu Natsionalnyi medychnyi universytet im.O.O.Bohomoltsia. https:\/\/base.uipv.org\/searchINV\/search. php?action=viewdetails&IdClaim=96367 [date access 20.05.2023] (In Ukrainian)."},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. Liu F, Qiu M, Zhai SD. Tolerability and effectiveness of (S)-amlodipine compared with racemic amlodipine in hypertension: a systematic review and meta-analysis. Curr Ther Res Clin Exp. 2010; 71(1):1-29. doi: 10.1016\/j.curtheres.2010.02.005.","DOI":"10.1016\/j.curtheres.2010.02.005"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. Park CG, Ahn TH, Cho EJ et al. Comparison of the Efficacy and Safety of Fixed-dose S-Amlodipine\/Telmisartan and Telmisartan in Hypertensive Patients Inadequately Controlled with Telmisartan: A Randomized, Double-blind, Multicenter Study. Clinical Therapeutics. 2016; 38 (10): 2185\u20132194. doi:10.1016\/j.clinthera.2016.09.006.","DOI":"10.1016\/j.clinthera.2016.09.006"},{"key":"ref14","unstructured":"15. Bychko MV, Bychka YaM. Sposib otsinky efektyvnosti likuvannia benidypinom khvorykh na ishemichnu khvorobu sertsia z stenokardiieiu ta arterialnoiu hipertenziieiu z porushenniam diastolichnoi funktsiieiu livoho shlunochka po \u00abhipertrofichnomu\u00bb typu [The method of evaluating the effectiveness of treatment with benidipine in patients with coronary heart disease with angina pectoris and arterial hypertension with impaired diastolic function of the left ventricle of the \u201chypertrophic\u201d type]. Patent na korysnu model \u211659603 vid 25.05.2011r, vlasnyk patentu UzhNU. https:\/\/base.uipv.org\/searchINV\/search.php?action=viewdetails&IdClaim=159007 [date access 20.05.2023] (In Ukrainian)."},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16. Kim DK, Ahn JH, Lee KH, et al. Ambulatory blood pressure response to S-amlodipine in Korean adult patients with uncontrolled essential hypertension: A prospective, observational study. J Clin Hypertens. 2022;24(3):350\u2013357. doi: 10.1111\/jch.14442.","DOI":"10.1111\/jch.14442"}],"container-title":["Wiadomo\u015bci Lekarskie"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T14:28:19Z","timestamp":1703168899000},"score":1,"resource":{"primary":{"URL":"https:\/\/wiadlek.pl\/wp-content\/uploads\/archive\/2023\/WiadLek2023i11.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":16,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023]]},"published-print":{"date-parts":[[2023,11]]}},"URL":"https:\/\/doi.org\/10.36740\/wlek202311114","archive":["Internet Archive"],"relation":{},"ISSN":["0043-5147"],"issn-type":[{"value":"0043-5147","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]}}}